To compare early and mid-term outcomes of heavyweight (HW) versus medium-weight (MW) mesh in minimally invasive extraperitoneal ventral hernia repair (VHR), with pragmatic recurrence at 1 year as the primary outcome.
Approach:
Design and data: Retrospective analysis of prospectively collected Abdominal Core Health Quality Collaborative registry data for adults undergoing laparoscopic or robotic retromuscular and/or preperitoneal VHR from 2013 through May 2025.
Eligibility: Included clean-wound repairs with successful fascial closure, uncoated permanent synthetic MW mesh (40–60 g/m²) or HW mesh (>75 g/m²), and at least 1 year of clinical or patient-reported follow-up.
Outcomes and analysis: The primary outcome was pragmatic recurrence at 1 year, combining available surgeon- and patient-reported assessments. Secondary outcomes included 30-day complications, recurrence, readmission, reoperation, pain, and quality of life. Propensity scores were use…
Key Findings:
The provided context describes the study rationale, methods, and planned outcomes but does not report comparative results for MW versus HW mesh.
Interpretation:
The study was designed to assess whether mesh weight is associated with recurrence and other outcomes after minimally invasive extraperitoneal VHR; no outcome estimates are available in the provided context.
Limitations:
The analysis was retrospective, despite use of prospectively collected registry data.
Eligibility required at least 1 year of follow-up, and recurrence assessments could be incomplete or discordant.
Follow-up rates were low beyond approximately 2 years, making the model unstable.
The provided context does not include study results.
Harold Burstein, MD, PhD, and Laura S. Dominici, MD, FACS, discuss highlights from the SENOMAC trial which sheds light on whether some patients with early breast cancer and limited lymph node involvement can safely avoid additional axillary surgery.
Breast cancer management is becoming increasingly biology-driven, with treatment decisions extending well beyond anatomic stage and conventional receptor classification.
